Connection

Eric Rovner to Muscarinic Antagonists

This is a "connection" page, showing publications Eric Rovner has written about Muscarinic Antagonists.
Connection Strength

3.510
  1. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemp Clin Trials. 2018 07; 70:83-87.
    View in: PubMed
    Score: 0.574
  2. New treatments for incontinence. Adv Chronic Kidney Dis. 2015 Jul; 22(4):279-88.
    View in: PubMed
    Score: 0.470
  3. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008 Sep; 180(3):1034-41.
    View in: PubMed
    Score: 0.290
  4. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008 Sep; 72(3):488-93.
    View in: PubMed
    Score: 0.290
  5. Trospium chloride: the European experience. Expert Opin Pharmacother. 2006 Jul; 7(10):1373-80.
    View in: PubMed
    Score: 0.252
  6. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr; 6(4):653-66.
    View in: PubMed
    Score: 0.231
  7. Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep. 2003 Oct; 4(5):385-90.
    View in: PubMed
    Score: 0.208
  8. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol. 2002 Jan; 41(1):6-14.
    View in: PubMed
    Score: 0.185
  9. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019 08; 36(8):1906-1921.
    View in: PubMed
    Score: 0.155
  10. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
    View in: PubMed
    Score: 0.084
  11. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010 May; 105(9):1276-82.
    View in: PubMed
    Score: 0.080
  12. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May; 105(9):1268-75.
    View in: PubMed
    Score: 0.079
  13. Frequently asked questions in the evaluation and management of overactive bladder. J Fam Pract. 2009 Oct; 58(10 Suppl):S1-11; quiz S12.
    View in: PubMed
    Score: 0.079
  14. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009 Sep; 182(3):1055-61.
    View in: PubMed
    Score: 0.078
  15. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19):2319-28.
    View in: PubMed
    Score: 0.065
  16. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006 Aug; 68(2):328-32.
    View in: PubMed
    Score: 0.063
  17. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006 May; 97(5):1003-6.
    View in: PubMed
    Score: 0.062
  18. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006 Apr; 67(4):731-6; discussion 736.
    View in: PubMed
    Score: 0.062
  19. Pharmacologic management of urinary incontinence in the female. Minerva Ginecol. 2004 Aug; 56(4):327-47.
    View in: PubMed
    Score: 0.055
  20. Trospium chloride in the management of overactive bladder. Drugs. 2004; 64(21):2433-46.
    View in: PubMed
    Score: 0.053
  21. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021 Oct; 13(4):425-434.
    View in: PubMed
    Score: 0.044
  22. BRL37344, a ?3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels. Urology. 2013 Sep; 82(3):744.e1-7.
    View in: PubMed
    Score: 0.026
  23. The management of overactive bladder syndrome. BMJ. 2012 Apr 17; 344:e2365.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.